Future Directions for CAR T-Cell Therapies in Solid Tumors
Michael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.
Michael Hurwitz, MD, PhD, associate professor of internal medicine (medical oncology) at Yale School of Medicine in New Haven, Connecticut, discusses the advances being made for the treatment of chimeric antigen receptor (CAR) T-cell therapies and next steps for evaluating the agent across solid tumors.
According to Hurwitz, CAR T cells may even be used in combination regimens for patients with a variety of cancers to enhance outcomes for patients. Though research is still needed, these developments are generating excitement in the field.
Hurwitz further presented on CAR T cells and their potential for patients with advanced renal cell carcinoma during the 2023 International Kidney Cancer Symposium.
Transcription:
0:10 | I think we're just looking for good things that kill off tumors as well. I think that CAR T seems, even though at this point they've been used for a few years, and they're approved and a bunch of different diseases, I think in solid tumors, there's still a way to go. But I think we're just at the beginning. There are phenomenal advances being made on the preclinical side, and making more complex cells that will be able to do a lot more things. They're going to be safer, they're going to be more specific, and they're going to have increased killing ability, and they're going to be able to survive in these sort of terrible microenvironments. These are all because of genetic changes you can make to these cells. It's not science fiction, but it's already getting into the realm of science fiction. I think that's what I'm excited for because these are the kinds of products that could target things in a way that we've never even thought of doing and in ways that are safe.
1:09 | The other thing is that soon we're going to, I don't know if it's soon, but at some point, we will be using it in combination with other therapies, and the combinations are going to be even better. We've really just begun, and I'm looking forward to a lot of technological changes in the future.
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More
